Molecular signatures define BAP1 -altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noaf105 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Philipp Sievers und 37 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelber…. Hauptthemen laut MEDLINE: Ubiquitin Thiolesterase, Meningioma, Tumor Suppressor Proteins, Meningeal Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Else Kröner-Fresenius-Stiftung.
Abstract (Originalsprache)
Background
Meningiomas are the most common primary intracranial neoplasms, with highly variable patient outcomes. While most meningiomas are benign, a significant subset recurs postoperatively, presenting substantial treatment challenges. BAP1 gene inactivation has been suggested as a marker for aggressive meningiomas, although its precise molecular and clinical roles remain poorly understood.
Methods
To comprehensively investigate BAP1-altered meningiomas, we used six meningiomas with known BAP1 alterations as a discovery set. Genome-wide DNA methylation profiling of these samples, along 11 151 reference meningiomas, identified a distinct molecular cluster (n = 42) using unsupervised visualization approaches. These tumors were further characterized by DNA/RNA sequencing, histopathological examination, and a retrospective review of clinical data, compared to reference meningioma cohorts, providing a thorough characterization of this rare tumor subtype.
Results
Our integrative analysis revealed BAP1-altered meningiomas as a distinct CNS tumor subtype, characterized by recurrent loss of chromosome 3p21 and driven by various BAP1-inactivating alterations. Although rhabdoid morphology is present in some cases, it is not exclusive and should not be used as a grading criterion. Progression-free survival analysis showed a median of 21 months (95% CI: 12-NA), with a 2-year overall survival rate of 79% (95% CI: 60%-100%), highlighting the aggressive nature of these tumors. Gene expression profiling revealed upregulation of PRC target genes, dysregulated Polycomb signaling, and elevated expression in several cellular and growth factor pathways.
Conclusions
BAP1-altered meningiomas represent a distinct and aggressive CNS tumor subtype associated with PRC dysregulation and recurrent 3p chromosome loss. These findings support the designation “meningioma, BAP1-altered.”
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
- Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Department of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Division of Pediatric Neurooncology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
ORCID-Profile: Philipp Sievers, Stefan Pusch, Martin Sill, Tibor Hortobagyi, Jens Schittenhelm, Matija Snuderl, Sebastian Brandner, Miriam Ratliff, Wolfgang Wick, Andreas von Deimling, Felix Sahm
Förderung
- NCI NIH HHS
- Else Kröner-Fresenius-Stiftung
Zitieren
APA
Sievers, P., Arora, S., Hielscher, T., Savran, D., Schrimpf, D., Banan, R., Vonhören, D., Pusch, S., Sill, M., Appay, R., Wirsching, H. G., Hortobagyi, T., Dohmen, H., Acker, T., Kohlhof-Meinecke, P., Schweizer, L., Wefers, A. K., Harter, P. N., Hartmann, C., …, & Sahm, F. (2025). Molecular signatures define BAP1 -altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf105
Vancouver
Sievers P, Arora S, Hielscher T, Savran D, Schrimpf D, Banan R, et al. Molecular signatures define BAP1 -altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf105
BibTeX
@article{Sievers2025,
author = {Sievers, Philipp and Arora, Sonali and Hielscher, Thomas and Savran, Dilan and Schrimpf, Daniel and Banan, Rouzbeh and Vonhören, David and Pusch, Stefan and Sill, Martin and Appay, Romain and Wirsching, Hans-Georg and Hortobagyi, Tibor and Dohmen, Hildegard and Acker, Till and Kohlhof-Meinecke, Patricia and Schweizer, Leonille and Wefers, Annika K and Harter, Patrick N and Hartmann, Christian and Beschorner, Rudi and Schittenhelm, Jens and Behling, Felix and Tabatabai, Ghazaleh and Mawrin, Christian and Snuderl, Matija and Maas, Sybren L N and Wesseling, Pieter and Brandner, Sebastian and Korshunov, Andrey and Ratliff, Miriam and Krieg, Sandro M and Wick, Wolfgang and Jones, David T W and Pfister, Stefan M and Holland, Eric C and von Deimling, Andreas and Szulzewsky, Frank and Sahm, Felix},
title = {Molecular signatures define BAP1 -altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noaf105}
}
EUVIMED